Production (Stage)
Aldeyra Therapeutics, Inc.
ALDX
$2.22
-$0.03-1.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.45% | -10.82% | -27.82% | -37.16% | -34.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.82% | 40.48% | -1.50% | -22.61% | -43.83% |
| Operating Income | -72.82% | -40.48% | 1.50% | 22.61% | 43.83% |
| Income Before Tax | -92.27% | -48.77% | 1.96% | 27.26% | 50.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -92.27% | -48.77% | 1.96% | 27.26% | 50.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -92.27% | -48.77% | 1.96% | 27.26% | 50.69% |
| EBIT | -72.82% | -40.48% | 1.50% | 22.61% | 43.83% |
| EBITDA | -73.37% | -40.76% | 1.49% | 22.70% | 44.01% |
| EPS Basic | -90.67% | -47.24% | 3.06% | 28.06% | 51.15% |
| Normalized Basic EPS | -90.71% | -47.26% | 3.05% | 28.06% | 51.16% |
| EPS Diluted | -90.67% | -47.24% | 3.06% | 28.06% | 51.15% |
| Normalized Diluted EPS | -90.71% | -47.26% | 3.05% | 28.06% | 51.16% |
| Average Basic Shares Outstanding | 0.85% | 0.92% | 1.03% | 1.03% | 0.97% |
| Average Diluted Shares Outstanding | 0.85% | 0.92% | 1.03% | 1.03% | 0.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |